BRE | Brain and reproductive organ-expressed (TNFRSF1A modulator) | Cancer-related genes Predicted intracellular proteins
| | | | | Expressed in all |
BRSK1 | BR serine/threonine kinase 1 | Enzymes Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
BSG | Basigin (Ok blood group) | Blood group antigen proteins CD markers Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Expressed in all |
BSND | Barttin CLCNK-type chloride channel accessory beta subunit | Disease related genes Predicted membrane proteins
| | | | | Tissue enriched |
BST2 | Bone marrow stromal cell antigen 2 | CD markers Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
BTBD8 | BTB (POZ) domain containing 8 | Predicted intracellular proteins
| | | | | Mixed |
BTLA | B and T lymphocyte associated | CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
BTN2A2 | Butyrophilin, subfamily 2, member A2 | Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
BTN3A3 | Butyrophilin, subfamily 3, member A3 | Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
BUB1B | BUB1 mitotic checkpoint serine/threonine kinase B | Cancer-related genes Disease related genes Enzymes Potential drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
BVES | Blood vessel epicardial substance | Predicted membrane proteins
| | | | | Tissue enhanced |
C12orf43 | Chromosome 12 open reading frame 43 | Predicted intracellular proteins
| | | | | Expressed in all |
C14orf159 | Chromosome 14 open reading frame 159 | Mitochondrial proteins Predicted intracellular proteins
| | | | | Expressed in all |
C14orf2 | Chromosome 14 open reading frame 2 | Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
C15orf27 | Chromosome 15 open reading frame 27 | Predicted membrane proteins
| | | | | Tissue enhanced |
C16orf89 | Chromosome 16 open reading frame 89 | Predicted secreted proteins
| | | | | Group enriched |
C16orf95 | Chromosome 16 open reading frame 95 | Predicted intracellular proteins
| | | | | Tissue enriched |
C19orf10 | Chromosome 19 open reading frame 10 | Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
C19orf24 | Chromosome 19 open reading frame 24 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
C1GALT1 | Core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 | Enzymes Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
C1orf159 | Chromosome 1 open reading frame 159 | Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
C1orf85 | Chromosome 1 open reading frame 85 | Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
C1QTNF6 | C1q and tumor necrosis factor related protein 6 | Predicted intracellular proteins
| | | | | Tissue enhanced |
C2CD2 | C2 calcium-dependent domain containing 2 | Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
C2CD5 | C2 calcium-dependent domain containing 5 | Predicted intracellular proteins
| | | | | Expressed in all |
C2orf82 | Chromosome 2 open reading frame 82 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
C3 | Complement component 3 | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
C4orf3 | Chromosome 4 open reading frame 3 | Predicted membrane proteins
| | | | | Not detected |
C4orf3 | Chromosome 4 open reading frame 3 | Predicted membrane proteins
| | | | | Mixed |
C5AR1 | Complement component 5a receptor 1 | CD markers G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
C5orf60 | Chromosome 5 open reading frame 60 | Predicted membrane proteins
| | | | | Tissue enriched |
C6orf47 | Chromosome 6 open reading frame 47 | Predicted membrane proteins
| | | | | Expressed in all |
C7orf26 | Chromosome 7 open reading frame 26 | Predicted intracellular proteins
| | | | | Expressed in all |
C7orf61 | Chromosome 7 open reading frame 61 | Predicted intracellular proteins
| | | | | Tissue enriched |
C8B | Complement component 8, beta polypeptide | Disease related genes Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
C9orf69 | Chromosome 9 open reading frame 69 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CA12 | Carbonic anhydrase XII | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CA14 | Carbonic anhydrase XIV | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1S | Calcium channel, voltage-dependent, L type, alpha 1S subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
CACNA2D1 | Calcium channel, voltage-dependent, alpha 2/delta subunit 1 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Mixed |
CACNG8 | Calcium channel, voltage-dependent, gamma subunit 8 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
CADM1 | Cell adhesion molecule 1 | Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
CADM2 | Cell adhesion molecule 2 | Predicted membrane proteins
| | | | | Tissue enriched |
CADM3 | Cell adhesion molecule 3 | Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
CADM4 | Cell adhesion molecule 4 | Predicted membrane proteins
| | | | | Tissue enhanced |
CALM2 | Calmodulin 2 (phosphorylase kinase, delta) | Cancer-related genes Disease related genes Plasma proteins Potential drug targets Predicted intracellular proteins RAS pathway related proteins Transporters
| | | | | Expressed in all |
CAMK2A | Calcium/calmodulin-dependent protein kinase II alpha | Enzymes Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |